UC-781

• Description :

  UC-781 (NSC 675186) is a highly potent and selective nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an IC50 value of 5 nM. UC-781 is stable under low PH or various temperatures conditions. UC-781 has antiviral activity and resistance[1][2][3].

• Product Name Alternative :

  NSC 675186

• UNSPSC :

  12352005

• Target :

  HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/uc-781.html

• Solubility :

  10 mM in DMSO

• Smiles :

  S=C(C1=C(C)OC=C1)NC2=CC=C(Cl)C(OC/C=C(C)/C)=C2

• Molecular Formula :

  C17H18ClNO2S

• Molecular Weight :

  335.85

• References & Citations :

  [1]Balzarini J, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS. 1998 Jul 9;12 (10) :1129-38. |[2]Van Herrewege Y, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004 Jan;48 (1) :337-9. |[3]Balzarini J, et al. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol. 1996 Aug;50 (2) :394-401. |[4]Fletcher P, et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79 (17) :11179-86.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  HIV-1

• CAS Number :

  [178870-32-1]